Page Title
Clinical Trial Finder
Observational Enrolling
Observational study of adults with cystic fibrosis for colorectal cancer screening (NICE-CF) (NICE-CF )
This observational study will compare stool-based testing to colonoscopy for colorectal cancer screening in people with CF. The study includes the collection of stool samples at home and a clinical screening colonoscopy.
Email a research coordinator to express interest in participating in this study.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
40 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For a more comprehensive list of eligibility criteria and details on this study, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Adults with CF 40 years of age or older, without history of transplant, or adults with CF age 30 or older who have had a transplant. Adults must be eligible for routine colon cancer screening and referred for screening or surveillance colonoscopy for colorectal cancer.
Study Design
-
Study Type: ?more info
Observational -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
6 months -
Number of Study Visits:
2
Additional Information
-
Phase: ?more info
Not Applicable -
Study Sponsor: ?more info
Hachem, Christine -
Study Drugs:
N/A
Study Sites
-
Enrolling
California
Stanford University Medical Center, STANFORD , CA 94305
Contact
Jacquelyn Spano
Phone: +1 (650) 721-1132
Email: jmzirbes@stanford.edu
-
Enrolling Soon
California
University of California Los Angeles, Santa Monica, CA 90404
Contact
Grant Turner
Phone: +1 (310) 449-0939
Email: gturner@mednet.ucla.edu
-
Enrolling
Colorado
National Jewish Health, Denver, CO 80206
Contact
Alix Wilson
Phone: +1 (303) 270-2517
Email: wilsona@njhealth.org
-
Enrolling Soon
Florida
University of Miami, Miami, FL 33136
Contact
Ylber Whitaker
Phone: +1 (305) 243-5545
Email: yiw2@miami.edu
-
Enrolling Soon
Kansas
University of Kansas Medical Center, Kansas City, KS 66160
Contact
Lawrence Scott
Phone: +1 (913) 588-4020
Email: lscott2@kumc.edu
-
Enrolling Soon
Maryland
Johns Hopkins University, Baltimore, MD 21205
Contact
Jeanne Pinto
Phone: +1 (443) 287-8983
Email: jpinto4@jh.edu
-
Enrolling Soon
Massachusetts
Massachusetts General Hospital, Boston, MA 02114
Contact
Margot Hardcastle
Phone: +1 (617) 726-3719
Email: mhardcastle@mgh.harvard.edu
-
Enrolling
Massachusetts
Boston Children's Hospital, Brigham & Women's Hospital, Boston, MA 02115
Contact
Robert Fowler
Phone: +1 (617) 355-1834
Email: Robert.fowler@childrens.harvard.edu
-
Enrolling
Michigan
University of Michigan Health System, Ann Arbor, MI 48109
Contact
Dawn Kruse
Phone: +1 (734) 615-3266
Email: dmkruse@med.umich.edu
-
Enrolling
Minnesota
The Minnesota Cystic Fibrosis Center, Minneapolis, MN 55455
Contact
Participant Contact University of Minnesota
Phone: +1
Email: cftrials@umn.edu
-
Enrolling
Missouri
Washington University School of Medicine, St. Louis, MO 63110
Contact
Irma Bauer
Phone: +1 (314) 747-2940
Email: irmabauer@wustl.edu
-
Enrolling
Missouri
SSM Health Saint Louis University Hospital, St. Louis, MO 63110
Contact
Freda Branch
Phone: +1 (314) 678-5468
Email: freda.branch@health.slu.edu
-
Enrolling Soon
New York
Columbia University Cystic Fibrosis Program, New York, NY 10032
Contact
Emily DiMango
Phone: +1 (212) 305-0290
Email: ead3@cumc.columbia.edu
-
Enrolling
North Carolina
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
Contact
Margret Powell
Phone: +1 (984) 974-2962
Email: margret_powell@med.unc.edu
-
Enrolling Soon
North Carolina
Atrium Health Pulmonary Care, Charlotte, NC 28204
Contact
Jessica Kearney-Bryan
Phone: +1 (704) 355-0244
Email: Jessica.kearney-bryan@atriumhealth.org
-
Enrolling
Ohio
Nationwide Children's Hospital, Columbus, OH 43205
Contact
Diana Gilmore
Phone: +1 (614) 722-4752
Email: diana.gilmore@nationwidechildrens.org
-
Enrolling
Ohio
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, OH 44106
Contact
Primary RC & Participant Contact General Contact
Phone: +1
Email: RainbowCFResearch@UHhospitals.org
-
Enrolling Soon
Oregon
Oregon Health Sciences University, Portland, OR 97239
Contact
Jenna Bucher
Phone: +1 (503) 494-7807
Email: bucherj@ohsu.edu
-
Enrolling
Pennsylvania
University of Pennsylvania, Philadelphia, PA 19104
Contact
Melissa Molter
Phone: +1 (215) 662-3116
Email: melissa.molter@pennmedicine.upenn.edu
-
Enrolling
South Carolina
Medical University of South Carolina, Charleston, SC 29425
Contact
Ashley Warden
Phone: +1 (843) 792-4349
Email: jonesash@musc.edu
-
Enrolling Soon
Tennessee
Vanderbilt University Medical Center, Nashville, TN 37232
Contact
Brijesh Patel
Phone: +1 (615) 343-4865
Email: brijesh.patel@vumc.org
-
Enrolling
Texas
University of Texas Southwestern, Dallas, TX 75390
Contact
Ashley Keller
Phone: +1 (214) 648-6233
Email: Ashley.Keller@UTSouthwestern.edu
-
Enrolling
Washington
University of Washington Medical Center, Seattle, WA 98195
Contact
Teresa Gambol
Phone: +1 (206) 543-7382
Email: TGambol@medicine.washington.edu
-
Enrolling
Wisconsin
Froedtert & Medical College of Wisconsin, Milwaukee, WI 53226
Contact
Erin Hubertz
Phone: +1 (414) 955-7019
Email: ehubertz@mcw.edu
Email a research coordinator to express interest in participating in this study.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
40 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For a more comprehensive list of eligibility criteria and details on this study, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Adults with CF 40 years of age or older, without history of transplant, or adults with CF age 30 or older who have had a transplant. Adults must be eligible for routine colon cancer screening and referred for screening or surveillance colonoscopy for colorectal cancer.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More